701977-09-5 Usage
Description
N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[(5-(trifluoromethyl)pyridin-2-yl)oxy]propanamide (MK 0364) is a chemical compound with the molecular formula C28H24ClF3N4O2. It is a potent and selective potassium channel opener, known for its potential therapeutic applications in treating neurological conditions such as epilepsy, neuropathic pain, anxiety, and depression. MK 0364 modulates the activity of specific potassium channels in the brain and nervous system, which can help reduce abnormal electrical activity and alleviate symptoms associated with these conditions. Its complex chemical structure and unique mode of action make it a promising candidate for further research and development in the field of neuroscience and drug discovery.
Uses
Used in Pharmaceutical Industry:
MK 0364 is used as a therapeutic agent for the treatment of neurological conditions such as epilepsy and neuropathic pain. Its application is based on its ability to modulate the activity of specific potassium channels in the brain and nervous system, which can help reduce abnormal electrical activity and alleviate symptoms associated with these conditions.
Used in Research and Development:
MK 0364 is used as a research compound for further investigation of its potential applications in treating anxiety and depression. Its unique mode of action and complex chemical structure make it a valuable candidate for exploring new therapeutic approaches in the field of neuroscience and drug discovery.
Used in Drug Discovery:
MK 0364 is employed as a lead compound in the development of new drugs targeting potassium channels for the treatment of various neurological conditions. Its potent and selective activity, along with its potential to alleviate symptoms associated with epilepsy, neuropathic pain, anxiety, and depression, make it a promising candidate for further optimization and development into effective therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 701977-09-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,0,1,9,7 and 7 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 701977-09:
(8*7)+(7*0)+(6*1)+(5*9)+(4*7)+(3*7)+(2*0)+(1*9)=165
165 % 10 = 5
So 701977-09-5 is a valid CAS Registry Number.
InChI:InChI=1/C27H25ClF3N3O2/c1-17(34-25(35)26(2,3)36-24-12-9-21(16-33-24)27(29,30)31)23(14-18-7-10-22(28)11-8-18)20-6-4-5-19(13-20)15-32/h4-13,16-17,23H,14H2,1-3H3,(H,34,35)
701977-09-5Relevant articles and documents
New efficient asymmetric synthesis of taranabant, a CB1R inverse agonist for the treatment of obesity
Crump, Brian R.,Phenix, Brian D.,Spindler, Felix,Wallace, Debra J.,Campos, Kevin R.,Shultz, C. Scott,Klapars, Artis,Zewge, Daniel,McWilliams, J. Christopher,Krska, Shane,Sun, Yongkui,Chen, Cheng-Yi
experimental part, p. 84 - 90 (2010/04/22)
Taranabant (1) is a cannabinoid-1 receptor (CB1R) inverse agonist that was recently in late-stage clinical development for the treatment of obesity. The previously employed synthesis exhibited a number of shortcomings for continuing development, and in th
Catalytic, enantioselective synthesis of taranabant, a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity
Chen, G-Yi,Frey, Lisa F.,Shultz, Scott,Wallace, Debra J.,Marcantonio, Karen,Payack, Joeseph F.,Vazquez, Enrique,Springfield, Shawn A.,Zhou, George,Liu, Ping,Kieczykowski, Gerard R.,Chen, Alex M.,Phenix, Brian D.,Singh, Utpal,Strine, Jeff,Izzo, Brianne,Krska, Shane W.
, p. 616 - 623 (2012/12/31)
Chiral amide 1 (MK-0364, taranabant) is a potent, selective, and orally bioavailable cannabinoid-1 receptor (CB-1R) inverse agonist indicated for the treatment of obesity. An asymmetric synthesis featuring a dynamic kinetic resolution via hydrogenation fo
Discovery of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1- methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity
Lin, Linus S.,Lanza Jr., Thomas J.,Jewell, James P.,Liu, Fing,Shah, Shrenik K.,Qi, Hongbo,Tong, Xinchun,Wang, Junying,Xu, Suoyu S.,Fong, Tung M.,Shen, Chun-Pyn,Lao, Julie,Xiao, Jing Chen,Shearman, Lauren P.,Stribling, D. Sloan,Rosko, Kimberly,Strack, Alison,Marsh, Donald J.,Feng, Yue,Kumar, Sanjeev,Samuel, Koppara,Yin, Wenji,Van Der Ploeg, Lex H. T.,Goulet, Mark T.,Hagmann, William K.
, p. 7584 - 7587 (2007/10/03)
The discovery of novel acyclic amide cannabinoid-1 receptor inverse agonists is described. They are potent, selective, orally bioavailable, and active in rodent models of food intake and body weight reduction. A major focus of the optimization process was to increase in vivo efficacy and to reduce the potential for formation of reactive metabolites. These efforts led to the identification of compound 48 for development as a clinical candidate for the treatment of obesity.
